[6-K] Pharvaris N.V. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Pharvaris (NASDAQ: PHVS) filed a Form 6-K reporting the voting outcomes of its Annual General Meeting held on 27 June 2025.

Shareholders approved every agenda item: (1) adoption of the Dutch statutory annual accounts for the fiscal year ended 31 December 2024; (2) appointment of PricewaterhouseCoopers Accountants N.V. as external independent auditor for fiscal 2025; (3) discharge of directors from liability for FY 2024; (4) extension of the Board’s authorization to repurchase shares and depository receipts; and (5) re-appointment of non-executive directors Dr. Meeker, Dr. Glassman, and Ms. Monges.

The filing contains no new financial results, strategic transactions, or material operational changes.

Insights

Corporate Governance Expert

TL;DR: Routine AGM approvals; limited direct investment impact.

The disclosure shows broad shareholder support for the existing governance structure—accounts adoption, auditor renewal, director discharge, board buy-back mandate, and three non-executive re-appointments all passed. No information was provided on the size or timing of the repurchase authorization, and no changes were made to executive leadership or strategic direction. Consequently, the filing is largely procedural and does not alter Pharvaris’s risk profile or near-term financial outlook.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-40010

Pharvaris N.V.

(Translation of registrant’s name into English)

Emmy Noetherweg 2

2333 BK Leiden

The Netherlands (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

PHARVARIS N.V.

Results of Annual General Meeting of Shareholders

On June 27, 2025, Pharvaris N.V. (the “Company”) held its Annual General Meeting of Shareholders (the “Annual General Meeting”). The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

Agenda Item 3

Adoption of Dutch statutory annual accounts for the fiscal year ended December 31, 2024. The Company’s shareholders adopted the Dutch statutory annual accounts for the fiscal year ended December 31, 2024.

Agenda Item 4

Appointment of PricewaterhouseCoopers Accountants N.V. as the Company’s external independent auditor for the fiscal year ending December 31, 2025. The Company’s shareholders appointed PricewaterhouseCoopers Accountants N.V. as the Company’s external independent auditor for the fiscal year ending December 31, 2025.

Agenda Item 5

Discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2024. The Company’s shareholders discharged the Company’s directors from liability with respect to the performance of their duties during the fiscal year ended December 31, 2024.

Agenda Item 7

Extension of authorization for the Company's board of directors to acquire shares and depository receipts for shares in the Company's capital. The Company’s shareholders extended the authorization to the Board to acquire shares and depository receipts for shares in the Company's capital.

Agenda Item 8

Re-appointment of Dr. Meeker as non-executive director of the Company. The Company’s shareholders re-appointed Dr. Meeker as non-executive director of the Company.

Agenda Item 9

Re-appointment of Dr. Glassman as non-executive director of the Company. The Company’s shareholders re-appointed Dr. Glassman as non- executive director of the Company.

Agenda Item 10

Re-appointment of Ms. Monges as non-executive director of the Company. The Company’s shareholders re-appointed Ms. Monges as non- executive director of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PHARVARIS N.V.
Date: June 27, 2025	By:	/s/ Berndt Modig
	Name:	Berndt Modig
	Title:	Chief Executive Officer

FAQ

Which agenda items were approved at Pharvaris's 27 June 2025 AGM?

Shareholders adopted the 2024 statutory accounts, appointed PwC as 2025 auditor, discharged directors, renewed the share-repurchase authorization, and re-appointed three non-executive directors.

Who will audit Pharvaris's financial statements for fiscal 2025?

PricewaterhouseCoopers Accountants N.V. was appointed as the external independent auditor for the year ending 31 December 2025.

Did Pharvaris shareholders authorize a share buyback in 2025?

Yes. The AGM extended the Board’s authorization to acquire shares and depository receipts in the company’s capital.

Which directors were re-appointed during the 2025 AGM?

Dr. Meeker, Dr. Glassman, and Ms. Monges were each re-appointed as non-executive directors.

Were Pharvaris directors discharged from liability for FY 2024?

Yes. Shareholders granted discharge for the directors’ performance during the fiscal year ended 31 December 2024.